Michael Greve’s for-profit endeavors include Kizoo Technology Ventures, an investment fund that focuses on biotech startups working on rejuvenation therapies targeting molecular damage outlined by the SENS view of aging. The non-profit side of his work intersects at the Rejuvenation Startup Summit events, where companies present their research under the guidance of the Forever Healthy Foundation staff. This year’s Summit in Berlin showcased promising projects with the potential to reverse aging by repairing cellular damage, outshining other less impactful efforts. Videos from the 2024 Summit are slowly being released online, offering a glimpse of the groundbreaking work presented by companies such as Deciduous Therapeutics, Mogling Bio, Revel Pharmaceuticals, Nanotics, cellvie, Intervene Immune, Rubedo Life Sciences, and more.
The CEO of Repair Biotechnologies highlighted significant advancements in reducing atherosclerotic plaque in mice, emphasizing the need for better treatments in humans. Current standard care for atherosclerosis falls short in significantly reducing plaque burden, leading to fatal cardiovascular events. Statin therapy fails to produce substantial improvements in plaque volume, leaving patients at risk. In contrast, mouse models showed a remarkable 17% reduction in plaque volume in just 6 weeks of treatment using LNP-mRNA gene therapy. This innovative approach targets excess free cholesterol accumulation, a common feature of aging and obesity. While excess free cholesterol is difficult to target with traditional drugs, research in mice shows promising results that could potentially be translated to humans.
